Wall Street brokerages expect Genomic Health (NASDAQ:GHDX) to announce $88.76 million in sales for the current quarter, according to Zacks. Seven analysts have issued estimates for Genomic Health’s earnings, with the lowest sales estimate coming in at $88.18 million and the highest estimate coming in at $89.10 million. Genomic Health reported sales of $83.98 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 5.7%. The business is expected to report its next earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Genomic Health will report full-year sales of $88.76 million for the current fiscal year, with estimates ranging from $367.32 million to $377.60 million. For the next fiscal year, analysts forecast that the company will post sales of $418.39 million per share, with estimates ranging from $406.85 million to $434.87 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Genomic Health.
Genomic Health (NASDAQ:GHDX) last released its quarterly earnings data on Thursday, March 8th. The medical research company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). Genomic Health had a negative net margin of 1.13% and a negative return on equity of 0.83%. The company had revenue of $87.50 million for the quarter, compared to analysts’ expectations of $88.96 million. During the same period in the previous year, the firm earned $0.04 earnings per share. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis.
GHDX has been the subject of several research reports. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “strong sell” rating in a report on Friday, March 9th. William Blair cut shares of Genomic Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, December 20th. ValuEngine raised shares of Genomic Health from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Barclays reaffirmed a “sell” rating and set a $28.00 target price on shares of Genomic Health in a report on Monday, January 8th. Finally, BidaskClub raised shares of Genomic Health from a “sell” rating to a “hold” rating in a report on Tuesday, December 19th. Four research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $32.67.
Shares of GHDX traded down $0.81 during mid-day trading on Wednesday, hitting $30.48. 155,926 shares of the company traded hands, compared to its average volume of 200,038. Genomic Health has a 1 year low of $26.54 and a 1 year high of $37.50. The stock has a market capitalization of $1,105.30, a price-to-earnings ratio of 3,011.00 and a beta of 0.63.
In other Genomic Health news, COO G Bradley Cole sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $35.51, for a total transaction of $177,550.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider James J. Vaughn sold 3,004 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $34.09, for a total transaction of $102,406.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 42,946 shares of company stock valued at $1,449,902. 46.20% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the business. Parametric Portfolio Associates LLC boosted its position in shares of Genomic Health by 5.8% in the second quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock worth $262,000 after purchasing an additional 441 shares during the period. Meeder Asset Management Inc. boosted its position in shares of Genomic Health by 120.7% in the fourth quarter. Meeder Asset Management Inc. now owns 2,960 shares of the medical research company’s stock worth $101,000 after purchasing an additional 1,619 shares during the period. New York State Common Retirement Fund boosted its position in shares of Genomic Health by 9.6% in the third quarter. New York State Common Retirement Fund now owns 22,900 shares of the medical research company’s stock worth $735,000 after purchasing an additional 2,000 shares during the period. University of Notre Dame DU Lac boosted its position in shares of Genomic Health by 3.0% in the third quarter. University of Notre Dame DU Lac now owns 82,503 shares of the medical research company’s stock worth $2,648,000 after purchasing an additional 2,368 shares during the period. Finally, SG Americas Securities LLC boosted its position in shares of Genomic Health by 43.2% in the third quarter. SG Americas Securities LLC now owns 8,769 shares of the medical research company’s stock worth $281,000 after purchasing an additional 2,647 shares during the period. Institutional investors and hedge funds own 89.99% of the company’s stock.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.